Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05694260 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
A Phase 2 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT05694260 is a Phase 2 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 31 participants.
The verdict
NCT05694260, a Phase 2 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
Interventions
- DRUG Bempedoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2023-01-12 |
| Est. Completion | 2025-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05694260
The ClinicalTrials.gov registry entry for NCT05694260 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bempedoic acid is the first listed.
NCT05694260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05694260 about?
NCT05694260 is a clinical study titled "A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)". Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
What is the current status of trial NCT05694260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2023-01-12. Estimated completion is 2025-06-04.
What interventions are being tested in trial NCT05694260?
The interventions under investigation include: Bempedoic acid (DRUG).
Who is sponsoring clinical trial NCT05694260?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.